Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
In people with MDS, the bone marrow stops making healthy blood cells and instead produces
poorly functioning, malformed, and immature blood cells. This can lead to anemia resulting
from too few healthy red blood cells, infection resulting from too few healthy white blood
cells, and bleeding resulting from too few healthy platelets. The exact cause of MDS remains
unknown, but it may be caused by abnormal autoimmune activity in which activated T cells, a
type of white blood cell, prevent normal bone marrow production. ATG, a medication that
inhibits immune function, can restore normal blood production in some people with MDS, but
it is not known how this happens and why it does not happen in all MDS patients. The purpose
of this study is to examine the effects of ATG in adults with MDS and to determine which
individuals with MDS are most likely to benefit from treatment with ATG.
Based on disease severity and likely disease progression, participants will be separated
into either a high-risk group or a low-risk group. Participants will be hospitalized for a
4-day period during which they will receive daily infusions of ATG. Oral prednisone will be
given 2 days before hospitalization, throughout hospitalization, and then for 14 days after
hospitalization to limit the side effects of ATG. Antihistamines and acetaminophen will also
be given during hospitalization to reduce the chances of an allergic reaction to ATG. After
discharge, all participants will attend monthly study visits that will include blood
collection, review of disease symptoms, and evaluation of medication response. At Week 16,
participants in the high-risk group will undergo additional blood collection, a bone marrow
biopsy, and a thorough evaluation of disease progression and the effects of MDS on daily
living abilities. Participants in the low-risk group will undergo these same procedures at
Week 24. Follow-up for all participants may last up to 2 years.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Bone marrow response and hematologic improvement
Measured at Week 16 or 24
No
Alan List, MD
Principal Investigator
H. Lee Moffitt Cancer Center
United States: Federal Government
RDCRN 5406
NCT00466843
April 2007
February 2010
Name | Location |
---|---|
H. Lee Moffitt Cancer Center | Tampa, Florida 33612 |
UCLA Oncology Center | Los Angeles, California 90095 |
Cleveland Clinic Foundation - Case Western University | Cleveland, Ohio 44195 |
Penn State University | Hershey, Pennsylvania 17033 |